Sweden
· Delayed Price · Currency is SEK OncoZenge AB Statistics
Total Valuation
OncoZenge AB has a market cap or net worth of SEK 50.37 million. The enterprise value is 46.50 million.
| Market Cap | 50.37M |
| Enterprise Value | 46.50M |
Important Dates
The next estimated earnings date is Friday, May 16, 2025.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoZenge AB has 11.71 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.47% |
| Owned by Institutions (%) | 16.17% |
| Float | 6.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50,366.95 |
| PB Ratio | 5.06 |
| P/TBV Ratio | 16.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.09
| Current Ratio | 3.09 |
| Quick Ratio | 2.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,171.25 |
Financial Efficiency
Return on equity (ROE) is -60.77% and return on invested capital (ROIC) is -37.97%.
| Return on Equity (ROE) | -60.77% |
| Return on Assets (ROA) | -34.17% |
| Return on Invested Capital (ROIC) | -37.97% |
| Return on Capital Employed (ROCE) | -87.29% |
| Revenue Per Employee | 500 |
| Profits Per Employee | -4.34M |
| Employee Count | 2 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.17% in the last 52 weeks. The beta is 1.46, so OncoZenge AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +6.17% |
| 50-Day Moving Average | 5.63 |
| 200-Day Moving Average | 5.86 |
| Relative Strength Index (RSI) | 36.52 |
| Average Volume (20 Days) | 51,324 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoZenge AB had revenue of SEK 1,000 and -8.69 million in losses. Loss per share was -0.74.
| Revenue | 1,000 |
| Gross Profit | 1,000 |
| Operating Income | -8.69M |
| Pretax Income | -8.69M |
| Net Income | -8.69M |
| EBITDA | n/a |
| EBIT | -8.69M |
| Loss Per Share | -0.74 |
Balance Sheet
The company has 3.86 million in cash and n/a in debt, giving a net cash position of 3.86 million or 0.33 per share.
| Cash & Cash Equivalents | 3.86M |
| Total Debt | n/a |
| Net Cash | 3.86M |
| Net Cash Per Share | 0.33 |
| Equity (Book Value) | 9.95M |
| Book Value Per Share | 0.85 |
| Working Capital | 3.10M |
Cash Flow
| Operating Cash Flow | -8.76M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -868,500.00% |
| Pretax Margin | -868,800.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoZenge AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -17.25% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoZenge AB has an Altman Z-Score of 11.84.
| Altman Z-Score | 11.84 |
| Piotroski F-Score | n/a |